Drugs / TRC253
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02987829 | May 2017 → Oct 2019 | castration-resistant prostate carcinoma, prostate adenocarcinoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRC253 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02987829 ↗ |
| Action | Inhibit | “with inhibitory activity against wild type AR” NCT02987829 ↗ |
| Modality | Small molecule | “TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR)” NCT02987829 ↗ |
| Route | Oral | “TRC253 is orally active” NCT02987829 ↗ |
| Target | AR | “antagonist of the androgen receptor (AR)” NCT02987829 ↗ |